Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

Pharmacogenomics

Volumn 10, Issue 11, 2009, Pages 1799-1817

  Ellis, Kyle J ^a   Stouffer, George A ^a   McLeod, Howard L ^a   Lee, Craig R ^a  

^a University of North Carolina   (United States)

Author keywords

Clopidogrel; CYP2C19; FDA; P glycoprotein; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Polymorphism; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CITALOPRAM; CLOPIDOGREL; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIAZEPAM; DRUG METABOLITE; ESOMEPRAZOLE; GLYCOPROTEIN P; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PRASUGREL; PROGUANIL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RABEPRAZOLE; VENLAFAXINE;

ACUTE CORONARY SYNDROME; ALLELE; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHARMACOGENOMICS; PRESCRIPTION; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RECEPTORS, PURINERGIC P2; RISK; TICLOPIDINE;

EID: 70749149366     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.143     Document Type: Review

References (98)

1. Rosamond W, Flegal K, Furie K et al.: Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), E25-E146 (2008).
2. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al.: 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2), 261-295 (2008).
3. Steinhubl SR, Berger PB, Mann JT 3rd et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411-2420 (2002).
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001). (Pubitemid 32758501)
5. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111(16), 2099-2106 (2005). (Pubitemid 40577905)
6. Lamb E: Top 200 Prescription Drugs of 2007. Pharmacy Times 74(5), 20-23 (2008).
7. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49(14), 1505-1516 (2007). (Pubitemid 46517957)
8. Angiolillo DJ, Guzman LA, Bass TA: Current antiplatelet therapies: benefits and limitations. Am. Heart J. 156(Suppl. 2), S3-S9 (2008).
9. Gladding P, Webster M, Ormiston J, Olsen S, White H: Antiplatelet drug nonresponsiveness. Am. Heart J. 155(4), 591-599 (2008).
10. Brandt JT, Payne CD, Wiviott SD et al.: A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66, E9-E16 (2007).
11. Matetzky S, Shenkman B, Guetta V et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25), 3171-3175 (2004). ■ Clopidogrel nonresponsiveness is associated with poor clinical outcome.
12. Wiviott SD, Trenk D, Frelinger AL et al.: Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923-2932 (2007). (Pubitemid 350291199)
13. Plosker GL, Lyseng-Williamson KA: Clopidogrel: a review of its use in the prevention of thrombosis. Drugs 67(4), 613-646 (2007).
14. Taubert D, von Beckerath N, Grimberg G et al.: Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 80(5), 486-501 (2006). ■ First study characterizing the contribution of P-glycoprotein to clopidogrel's bioavailability, and reporting that the ABCB1 3435C>T polymorphism is associated with clopidogrel pharmacokinetics and pharmacodynamics.
15. Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31(1), 53-59 (2003).
16. Kurihara A, Hagihara K, Kazui M, Ozeki T, Farid NA, Ikeda T: In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidative steps involved in the active metabolite formation. Drug Metab. Rev. 37(Suppl. 2), 99 (2005).
17. Hagihara K, Kazui M, Yoshiike M, Honda K, Farid NA, Kurihara A: Abstract 4020: a possible mechanism of poorer and more variable response to clopidogrel than prasugrel. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8-12 November (2008).
18. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002). (Pubitemid 35168437)
19. Xie HG, Kim RB, Wood AJ, Stein CM: Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
20. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269(22), 15419-15422 (1994). ■ Discovery and initial functional characterization of the CYP2C19*2 variant allele.
21. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46(4), 594-598 (1994). (Pubitemid 24334747)
22. Sim SC, Risinger C, Dahl ML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79(1), 103-113 (2006). (Pubitemid 43069582)
23. Brandt JT, Close SL, Iturria SJ et al.: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12), 2429-2436 (2007). ■ First study to report an association between CYP2C19*2 variant allele and clopidogrel pharmacokinetics.
24. Kim KA, Park PW, Hong SJ, Park JY: The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin. Pharmacol. Ther. 84(2), 236-242 (2008).
25. Umemura K, Furuta T, Kondo K: The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb. Haemost. 6(8), 1439-1441 (2008). (Pubitemid 352016331)
26. Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009). ■ Post-hoc ana lysis of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which reported that CYP2C19 genotype is associated with clinical outcome in acute coronary syndrome patients with planned percutaneous coronary intervention.
27. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23), 2908-2913 (2003).
28. Michelson AD: Platelet function testing in cardiovascular diseases. Circulation 110(19), E489-E493 (2004).
29. Michelson AD: Methods for the measurement of platelet function. Am. J. Cardiol. 103(Suppl. 3), A20-A26 (2009).
30. Michelson AD, Frelinger AL 3rd, Furman MI: Current options in platelet function testing. Am. J. Cardiol. 98(10A), N4-N10 (2006).
31. Hulot JS, Bura A, Villard E et al.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7), 2244-2247 (2006). ■ First study to report higher platelet function in healthy CYP2C19*2 variant allele carriers after clopidogrel dosing. (Pubitemid 44497506)
32. Fontana P, Senouf D, Mach F: Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb. Res. 121(4), 463-468 (2008). (Pubitemid 351174278)
33. Frere C, Cuisset T, Morange PE et al.: Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am. J. Cardiol. 101(8), 1088-1093 (2008).
34. Geisler T, Schaeffeler E, Dippon J et al.: CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9(9), 1251-1259 (2008).
35. Giusti B, Gori AM, Marcucci R et al.: Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17(12), 1057-1064 (2007). (Pubitemid 351339490)
36. Trenk D, Hochholzer W, Fromm MF et al.: Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J. Am. Coll. Cardiol. 51(20), 1925-1934 (2008). ■ First study suggesting a potential association between CYP2C19 genotype and clinical outcome in patients receiving clopidogrel after elective percutaneous coronary intervention.
37. Geisler T, Grass D, Bigalke B et al.: The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J. Thromb. Haemost. 6(1), 54-61 (2008).
38. Shuldiner AR, O'Connell JR, Bliden KP et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
39. Hochholzer W, Trenk D, Bestehorn HP et al.: Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742-1750 (2006). (Pubitemid 44648629)
40. Bhatt DL, Scheiman J, Abraham NS et al.: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118(18), 1894-1909 (2008).
41. Ho PM, Maddox TM, Wang L et al.: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9), 937-944 (2009). ■ Observational ana lysis reporting an association between proton-pump inhibitor use and poor clinical outcome in acute coronary syndrome patients receiving clopidogrel.
42. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J: Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost. 4(11), 2508-2509 (2006). (Pubitemid 44575451)
43. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos. 32(8), 821-827 (2004). (Pubitemid 38955611)
44. Blume H, Donath F, Warnke A, Schug BS: Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 29(9), 769-784 (2006). (Pubitemid 44352242)
45. Gilard M, Arnaud B, Cornily JC et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51(3), 256-260 (2008). ■ First study to report that co-administration of omeprazole can impair clopidogrel's antiplatelet effects.
46. Barragan P, Bouvier JL, Roquebert PO et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc. Interv. 59(3), 295-302 (2003). (Pubitemid 36792384)
47. O'Donoghue ML, Braunwald E, Antman EM et al.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an ana lysis of two randomised trials. Lancet 374(9694), 989-997 (2009).
48. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B: Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157(1), 148.E1-E5 (2009).
49. Small DS, Farid NA, Payne CD et al.: Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48(4), 475-484 (2008).
50. Lau WC, Waskell LA, Watkins PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107(1), 32-37 (2003).
51. Farid NA, Small DS, Payne CD et al.: Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 28(12), 1483-1494 (2008).
52. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD: Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109(11), 1335-1338 (2004). (Pubitemid 38387816)
53. Saw J, Steinhubl SR, Berger PB et al.: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary ana lysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8), 921-924 (2003). (Pubitemid 37048218)
54. Vinholt P, Poulsen TS, Korsholm L et al.: The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb. Haemost. 94(2), 438-443 (2005). (Pubitemid 41122501)
55. Farid NA, Payne CD, Small DS et al.: Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. 81(5), 735-741 (2007).
56. Siller-Matula JM, Lang I, Christ G, Jilma B: Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol. 52(19), 1557-1563 (2008).
57. Lau WC, Gurbel PA, Watkins PB et al.: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109(2), 166-171 (2004).
58. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. 26(8), 1895-1900 (2006).
59. Fontana P, Hulot JS, De Moerloose P, Gaussem P: Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost. 5(10), 2153-2155 (2007). (Pubitemid 47450038)
60. Nakamura T, Sakaeda T, Horinouchi M et al.: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71(4), 297-303 (2002). (Pubitemid 34311459)
61. Ishikawa T, Tsuji A, Inui K et al.: The genetic polymorphism of drug transporters: functional ana lysis approaches. Pharmacogenomics 5(1), 67-99 (2004). (Pubitemid 38088481)
62. Tang K, Ngoi SM, Gwee PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12(6), 437-450 (2002). (Pubitemid 34913526)
63. Fontana P, Dupont A, Gandrille S et al.: Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108(8), 989-995 (2003). (Pubitemid 37048230)
64. Malek LA, Kisiel B, Spiewak M et al.: Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ. J. 72(7), 1165-1169 (2008). (Pubitemid 351957086)
65. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al.: Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb. Res. 116(6), 491-497 (2005). (Pubitemid 41330814)
66. Cuisset T, Frere C, Quilici J et al.: Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb. Res. 120(6), 893-899 (2007). (Pubitemid 47432706)
67. Collet JP, Hulot JS, Pena A et al.: Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009). ■ Presence of the CYP2C19*2 allele is associated with poor clinical outcome in post-myocardial infarction patients on clopidogrel therapy.
68. Giusti B, Gori AM, Marcucci R et al.: Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103(6), 806-811 (2009).
69. Sibbing D, Stegherr J, Latz W et al.: Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30(8), 916-922 (2009).
70. Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009). ■ CYP2C19 and ABCB1 genotype are associated with clinical outcome in post-myocardial infarction patients treated with clopidogrel.
71. Wiviott SD, Braunwald E, McCabe CH et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
72. Juurlink DN, Gomes T, Ko DT et al.: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7), 713-718 (2009).
73. Aubert RE, Epstein RS, Teagarden JR et al.: Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcome study. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8-12 November (2008).
74. Dunn SP, Macaulay TE, Brennan DM et al.: Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Presented at: American Heart Association Scientific Sessions. New Orleans, LA, USA, 8-12 November (2008).
75. Ang L, Palakodeti V, Khalid A et al.: Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J. Am. Coll. Cardiol. 52(13), 1052-1059 (2008).
76. Angiolillo DJ, Bernardo E, Ramirez C et al.: Insulin therapy is associated with platelet dysfunction in patients with Type 2 diabetes mellitus on dual oral antiplatelet treatment. J. Am. Coll. Cardiol. 48(2), 298-304 (2006). (Pubitemid 44026661)
77. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N: Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am. J. Cardiol. 100(2), 203-205 (2007). (Pubitemid 47041981)
78. Wiviott SD, Braunwald E, Angiolillo DJ et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38. Circulation 118(16), 1626-1636 (2008).
79. Moreno PR, Fuster V: New aspects in the pathogenesis of diabetic atherothrombosis. J. Am. Coll. Cardiol. 44(12), 2293-2300 (2004).
80. Ferreira IA, Mocking AI, Feijge MA et al.: Platelet inhibition by insulin is absent in Type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 26(2), 417-422 (2006).
81. Erlinge D, Varenhorst C, Braun OO et al.: Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll. Cardiol. 52(24), 1968-1977 (2008).
82. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M: Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89(5), 783-787 (2003). (Pubitemid 36603418)
83. Blindt R, Stellbrink K, de Taeye A et al.: The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost. 98(6), 1329-1334 (2007). (Pubitemid 350239106)
84. Bonello L, Paganelli F, Arpin-Bornet M et al.: Vasodilator-stimulated phosphoprotein phosphorylation ana lysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5(8), 1630-1636 (2007). (Pubitemid 47091403)
85. Frere C, Cuisset T, Quilici J et al.: ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb. Haemost. 98(4), 838-843 (2007). (Pubitemid 47555077)
86. Malinin A, Pokov A, Spergling M et al.: Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb. Res. 119(3), 277-284 (2007). (Pubitemid 44918092)
87. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52(14), 1128-1133 (2008).
88. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD: Platelet function monitoring in patients with coronary artery disease. J. Am. Coll. Cardiol. 50(19), 1822-1834 (2007).
89. Kuliczkowski W, Witkowski A, Polonski L et al.: Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 30(4), 426-435 (2009).
90. Gladding P, Webster M, Zeng I et al.: The pharmacogenetics and pharmacodynamics of clopidogrel response: an ana lysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1(6), 620-627 (2008).
91. Angiolillo DJ, Shoemaker SB, Desai B et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6), 708-716 (2007). (Pubitemid 46294761)
92. Mehta SR: On behalf of the CURRENT OASIS-7 investigators: A 2X2 factorial randomized trial of optimal clopidogrel and aspirin dosing in patients with ACS undergoing an early invasive strategy with intent for PCI. Presented at: European Society of Cardiology 2009 Congress. Barcelona, Spain, 20-30 August (2009).
93. Pena A, Collet JP, Hulot JS et al.: Can we override clopidogrel resistance? Circulation 119(21), 2854-2857 (2009).
94. Mega JL, Close SL, Wiviott SD et al.: Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
95. Jeong YH, Lee SW, Choi BR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high posttreatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53(13), 1101-1109 (2009).
96. Chen KY, Rha SW, Li YJ et al.: Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 119(25), 3207-3214 (2009).
97. US FDA: Plavix® (clopidogrel bisulfate) 75 mg tablets: Safety Labeling Changes Approved by FDA Center for Drug Evaluation and Research (CDER) www.fda.gov/Safety/MedWatch/SafetyInformation/ucm165166.htm (Accessed June 2009)
98. Homepage of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se/ (Accessed June 2009)